The two groups of patients were followed up for 6 months , 8 cases of major adverse cardiovascular events occurred in clopidogrel group , 2 cases of major adverse cardiovascular events occurred in ticagrelor group , and there was significant difference between the two groups ( P < 0.05 ) .